Transparency Market

Research
Peptide Therapeutics Market is
growing at a CAGR of 8.7% from
2!" to 2!#. $% Transparenc%
Market Research.
Single User License:
USD 4595
Multi User License:
USD 7595
Corporate User License:
USD 10595
Peptide Therapeutics Market is &'pected to Reach ()* 2+.,
$i--ion G-o.a--% in 2!8/ Transparenc% Market Research
Transparency Market Research
)tate Tower0
#0 )tate )treet0 )uite 7.
A-.an%0 12 !227
(nited )tates
www.transparenc%marketresearch.com
sa-es3transparenc%marketresearch.com
128 Page Report
Pulis!e" Date
1#$Marc!$201#
%u& 'o(
Re)uest Sa*ple
Press Release
Peptide Therapeutics
Market
Peptide Therapeutics Market was valued at USD 14.1 billion in 2013 and is estiated to reach a
arket worth USD 2!.4 billion in 201" at a #$%& o' (.)* 'ro 2013 to 201".
%ro(se t!e +ull report at !ttp:,,(((-transparenc&*ar.etresearc!-co*,pepti"e$
t!erapeutics$*ar.et-!t*l
The +rowth o' the arket is driven b, 'actors such as risin+ incidences o' cardiovascular
diseases- etabolic diseases and technolo+ical enhanceent in peptide s,nthesis. The $sian
re+ion o.ers 'uture +rowth prospects to the peptide industr, owin+ to vast unet edical needs
and risin+ disposable incoe o' patients.
$on+st the application arket- the cancer peptide se+ent accounted 'or the lar+est share o'
appro/iatel, 21* and is e/pected to +row at a health, #$%& durin+ the 'orecast period. The
neuropeptides application se+ent is anticipated to +row at a #$%& o' ".4* 'ro 2012 to 201(
due to the rise in nuber o' neurolo+ical disorders such as $l0heier1s and Parkinson1s disease.
The parenteral route o' adinistration o' peptides accounted 'or the lar+est share o' around (2*
in ,ear 2011- in ters o' routes o' adinistration3 however other routes o' adinistration like
oral- pulonar,- nasal and intraderal are also bein+ tested and are estiated to e/perience
health, +rowth rate durin+ the 'orecast period.
Technolo+ical enhanceent with introduction o' h,brid technolo+, alon+ with solid phase peptide
s,ntheses 4SPPS5 is e/pected to enhance the +rowth o' peptide therapeutics. The h,brid
technolo+, se+ent which provides the best o' both solid and li6uid s,ntheses is now bein+
adopted b, a7or pla,ers and hence this arket is e/pected to see the hi+hest +rowth o' 12.1*
'ro 2012 to 201(.
Transparenc% Market Research
2
R/P0R1 D/SCR2P120'
Peptide Therapeutics
Market
The 8orth $erican peptide therapeutics arket held a7orit, o' the arket share o'
appro/iatel, 40* in 2011 owin+ to its developed econo,. 9owever- due to rise in cost
containent and bud+etar, cuts in 8orth $erica- eer+in+ countries such as :ndia- #hina and
other ;atin $erican countries is e/pected to see a health, +rowth in the stud, period.
Soe o' the ke, arket pla,ers are <li ;ill,- &oche- $,lin- 8ovo=8ordisk- :psen and others. The
contract anu'acturin+ or+ani0ation 4#M>5 industr, includes a7or pla,ers such as ?ache-
Pol,peptide %roup- ;on0a- Peptis,ntha and others.
Peptide Therapeutics Market- b, $pplications
#ancer
Metabolic
#ardiovascular
Deratolo+,
$nti=:n'ection
8eurolo+,
%astro :ntestinal
&enal
&espirator,
Pain
>thers
Peptide Therapeutics Market- b, &oute o' $dinistration
Parenteral
>ral
Pulonar,
Transparenc% Market Research
3
Peptide Therapeutics
Market
Mucosal
>thers
Peptide Therapeutics Market- b, T,pes
:nnovative
%enerics
Peptide Therapeutics Market- b, $P: Peptide
:n=9ouse
#M> 4#ontract Manu'acturin+ >r+ani0ation5
Peptide Therapeutics b, technolo+,
;i6uid Phase Peptide S,nthesis 4;PPS5
Solid Phase Peptide S,nthesis 4SPPS5
9,brid
Peptide Therapeutics Market- b, %eo+raph,
8orth $erica
<urope
$sia
&o@
3or Sa*ple Report 4isit 0n:
http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=!"
Transparenc% Market Research
4
Peptide Therapeutics
Market
C!apter 1 2ntro"uction
1-1 Report "escription
1-2 Mar.et seg*entation
1-# Scope o+ t!e report
1-4 Researc! *et!o"olog&
1-5 5ssu*ptions
C!apter 2 /6ecuti7e Su**ar&
2-1 8loal pepti"e t!erapeutics *ar.et re7enues9 2010 : 2018 ;USD Million<
2-1-1 8loal pepti"e t!erapeutics *ar.et re7enues9 & region9 2010 $ 2018 ;USD Million<
2-1-2 8loal 5P2 pepti"e t!erapeutics *ar.et9 2011 ;USD Million<
2-1-# 8loal pepti"e t!erapeutics *ar.et9 & route o+ a"*inistration9 2011 = 2018 ;><
C!apter # 8loal Pepti"e 1!erapeutics Mar.et D&na*ics
#-1 07er7ie(
#-2 Dri7ers
#-2-1 2ncrease in cancer patient population to propel t!e gro(t! o+ ne( pepti"es
Transparenc% Market Research
!
15%L/ 03 C0'1/'1
Peptide Therapeutics
Market
#-2-2 Rise in *etaolic "isor"ers to escalate t!e gro(t! o+ pepti"es *ar.et
#-2-# Rise in R=D pipeline o+ pepti"e "rugs is e6pecte" to ring consi"erale gro(t! in
co*ing &ears
#-2-#-1 8loal pepti"e t!erapeutics trials gro(t!9 1970 $ 2011
#-2-4 1ec!nological en!ance*ent !as ooste" t!e gro(t! o+ t!e *ar.et (it! ra"ical
re"uction in total pro"uction cost o+ pepti"es
#-# Restraints = c!allenges
#-#-1 2ncreasing co*ple6it& o+ pepti"es is a !uge c!allenge +or *anu+acturers
#-#-2 Lac. o+ regulator& stan"ar"s !a*pering t!e gro(t! o+ t!e *ar.et
#-#-# Matc!ing e)uip*ents (it! custo*er re)uire*ents is a *a?or c!allenge +or 5P2
pepti"e *anu+acturers
#-4 0pportunities
#-4-1 Rise in cancer 7accine to "ri7e t!e +uture *ar.et
#-4-2 8eneric pepti"es *ar.et to @ouris! (it! patent cliA e6pecte" in t!e +orecast perio"
#-4-# S*all iotec! Br*s collaorating (it! large p!ar*aceutical co*panies to e6plore
+urt!er gro(t!
#-4-#-1 8loal scenario o+ ac)uisitions o+ iotec! Br*s & large p!ar*a giants
#-4-#-2 Ma?or pepti"e "rugs an" sales9 2011 ;USD Million<
#-5 Porters B7e +orces anal&sis
#-5-1 PorterCs B7e +orces anal&sis o+ gloal pepti"e t!erapeutics *ar.et
#-5-2 %argaining po(er o+ suppliers
Transparenc% Market Research
2
Peptide Therapeutics
Market
#-5-# %argaining po(er o+ u&ers
#-5-4 1!reat o+ ne( entrants
#-5-5 1!reat o+ sustitutes
#-5-D Co*petiti7e ri7alr&
#-D Mar.et attracti7eness anal&sis
#-D-1 Mar.et attracti7eness anal&sis o+ t!e pepti"e t!erapeutics *ar.et & geograp!&
#-7 Pepti"e t!erapeutics $ e*erging tec!nologies = tren"s
#-8 Regulator& policies
C!apter 4 8loal Pepti"e 1!erapeutics Mar.et 5nal&sis9 %& 5pplications
4-1 2ntro"uction
4-1-1 8loal pepti"e t!erapeutics *ar.et re7enue9 & applications 2012$2018 ;USD Million<
4-1-2 Cancer
4-1-2-1 8loal cancer pepti"e t!erapeutics pipeline "rugs anal&sis9 nu*er o+ trials9
2009 $ 2012
4-1-2-2 8loal cancer pepti"e t!erapeutics *ar.et re7enues9 2010 : 2018 ;USD
Million<
4-1-# Metaolic
4-1-#-1 8loal *etaolic pepti"e t!erapeutics pipeline "rugs anal&sis9 nu*er o+
trials9 2009 $ 2012
Transparenc% Market Research
)
Peptide Therapeutics
Market
4-1-#-2 8loal *etaolic pepti"e t!erapeutics *ar.et re7enues9 2010 : 2018 ;USD
Million<
4-1-4 Car"io7ascular
4-1-4-1 8loal car"io7ascular pepti"e t!erapeutics pipeline "rugs anal&sis9 nu*er o+
trials9 2009 $ 2012
4-1-4-2 8loal car"io7ascular pepti"e t!erapeutics *ar.et re7enues9 2010 : 2018
;USD Million<
4-1-5 Der*atolog&
4-1-5-1 8loal "er*atolog& pipeline "rugs anal&sis9 nu*er o+ trials9 2009 $ 2012
4-1-5-2 8loal "er*atolog& pepti"es *ar.et re7enues9 2010 : 2018 ;USD Million<
4-1-D 5nti$2n+ection
4-1-D-1 8loal anti$in+ection "rugs anal&sis9 nu*er o+ trials9 2009 $ 2012
4-1-D-2 8loal anti$in+ection pepti"es *ar.et re7enues9 2010 : 2018 ;USD Million<
4-1-7 'eurolog&
4-1-7-1 8loal neurolog& pipeline "rugs anal&sis9 nu*er o+ trials9 2009 $ 2012
4-1-7-2 8loal neurolog& pepti"es *ar.et re7enues9 2010 : 2018 ;USD Million<
4-1-8 8astro 2ntestinal
4-1-8-1 8loal gastro intestinal pipeline "rugs anal&sis9 nu*er o+ trials9 2009 $ 2012
4-1-8-2 8loal gastro intestinal pepti"es *ar.et re7enues9 2010 $ 2018 ;USD Million<
4-1-9 Renal
4-1-9-1 8loal renal pipeline "rugs anal&sis9 nu*er o+ trials9 2009 $ 2012
Transparenc% Market Research
(
Peptide Therapeutics
Market
4-1-9-2 8loal renal pepti"es *ar.et re7enues9 2010 : 2018 ;USD Million<
4-1-10 Respirator&
4-1-10-1 8loal respirator& pipeline "rugs anal&sis9 nu*er o+ trials9 2009 $ 2012
4-1-10-2 8loal respirator& pepti"es *ar.et re7enues9 2010 : 2018 ;USD Million<
4-1-11 Pain
4-1-11-1 8loal pain pipeline "rugs anal&sis9 nu*er o+ trials9 2009 $ 2012
4-1-11-2 8loal pain pepti"es *ar.et re7enues9 2010 $ 2018 ;USD Million<
4-1-12 0t!ers
4-1-12-1 8loal ot!er pipeline "rugs anal&sis9 nu*er o+ trials9 2009 $ 2012
4-1-12-2 8loal ot!er pepti"es *ar.et re7enues9 2010 : 2018 ;USD Million<
C!apter 5 8loal Pepti"e 1!erapeutics Mar.et9 & Route o+ 5"*inistration
5-1 2ntro"uction
5-1-1 8loal pepti"e t!erapeutics *ar.et re7enues9 & route o+ a"*inistration9 2010 $ 2018
;USD Million<
5-1-2 Met!o"s o+ "eli7er& +or pepti"e "rugs
5-2 Parenteral Route
5-2-1 8loal pepti"e t!erapeutics *ar.et re7enues9 & parenteral route o+ a"*inistration9
2010 $ 2018 ;USD Million<
5-# 0ral Route
Transparenc% Market Research
"
Peptide Therapeutics
Market
5-#-1 8loal pepti"e t!erapeutics *ar.et re7enues9 & oral route o+ a"*inistration9 2010 $
2018 ;USD Million<
5-4 Pul*onar& Route
5-4-1 8loal pepti"e t!erapeutics *ar.et re7enues9 & pul*onar& route o+ a"*inistration9
2010 $ 2018 ;USD Million<
5-5 Mucosal Route
5-5-1 8loal pepti"e t!erapeutics *ar.et re7enues9 & *ucosal route o+ a"*inistration9
2010 $ 2018 ;USD Million<
5-D 0t!ers ;2ntra"er*al = 'asal<
5-D-1 8loal pepti"e t!erapeutics *ar.et re7enues9 & ot!er routes o+ a"*inistration9
2010 $ 2018 ;USD Million<
C!apter D Pepti"e 1!erapeutics Mar.et : 8eneric = 2nno7ati7e Seg*ents
D-1 2ntro"uction
D-1-1 8loal pepti"e t!erapeutics *ar.et9 & t&pes re7enues9 2010 $ 2018 ;USD *illion<
D-2 Pepti"e 1!erapeutics : 2nno7ati7e *ar.et
D-2-1 8loal inno7ati7e pepti"e t!erapeutics *ar.et re7enues9 2010 $ 2018 ;USD Million<
D-# Pepti"e 1!erapeutics : 8eneric *ar.et
D-#-1 8loal generic pepti"e t!erapeutics *ar.et re7enues9 2010 $ 2018 ;USD Million<
C!apter 7 5P2 Pepti"e 1!erapeutics Mar.et9 2n$!ouse 4s CM0
Transparenc% Market Research
10
Peptide Therapeutics
Market
7-1 2ntro"uction
7-2 5P2 pepti"e t!erapeutics : 2n$!ouse *ar.et
7-2-1 8loal 5P2 pepti"e t!erapeutics in$!ouse *ar.et re7enues9 2010$2018 ;USD Million<
7-# Contract Manu+acturing 0rganiEations ;CM0<
7-#-1 8loal 5P2 pepti"e t!erapeutics CM0s *ar.et re7enues9 2010 $ 2018 ;USD Million<
C!apter 8 Pepti"e 1!erapeutics Mar.et9 %& 1ec!nolog&
8-1 2ntro"uction
8-1-1 8loal pepti"e t!erapeutics *ar.et re7enues9 & tec!nolog&9 2010 : 2018 ;USD
Million<
8-2 Soli" P!ase Pepti"e S&nt!esis ;SPPS<
8-2-1 8loal pepti"e t!erapeutics SPPS tec!nolog& *ar.et re7enues9 2010 $ 2018 ;USD
Million<
8-# Li)ui" P!ase Pepti"e S&nt!esis ;LPPS<
8-#-1 8loal pepti"e t!erapeutics LPPS tec!nolog& *ar.et re7enues9 2010 $ 2018 ;USD
Million<
8-4 F&ri" 1ec!nolog&
8-4-1 8loal pepti"e t!erapeutics !&ri" tec!nolog& *ar.et re7enues9 2010 $ 2018 ;USD
Million<
C!apter 9 Pepti"e 1!erapeutics Mar.et9 %& 8eograp!&
Transparenc% Market Research
11
Peptide Therapeutics
Market
9-1 2ntro"uction
9-1-1 8loal pepti"e t!erapeutics *ar.et s!are9 & geograp!&9 2011 $ 2018
9-2 'ort! 5*erica
9-2-1 'ort! 5*erica pepti"e t!erapeutics *ar.et re7enues9 2010 : 2018 ;USD Million<
9-# /urope
9-#-1 /urope pepti"e t!erapeutics *ar.et re7enues9 2010 : 2018 ;USD Million<
9-4 5sia
9-4-1 5sia pepti"e t!erapeutics *ar.et re7enues9 2010 $ 2018 ;USD Million<
9-5 Rest o+ Gorl"
9-5-1 RoG pepti"e t!erapeutics *ar.et re7enues9 2010 $ 2018 ;USD Million<
C!apter 10 Mar.et S!are 5nal&sis
10-1 Mar.et s!are & .e& pla&ers
10-2 Mar.et s!are & .e& pla&ers in pepti"e "rugs *ar.et
10-2-1 8loal pepti"e t!erapeutics *ar.et s!are anal&sis o+ .e& pla&ers9 2011 ;><
10-# Mar.et s!are & .e& pla&ers in CM0 seg*ent
10-#-1 8loal pepti"e t!erapeutics: *ar.et s!are anal&sis o+ .e& CM0 pla&ers9 2011 ;><
C!apter 11 Reco**en"ations
11-1 Success strategies
Transparenc% Market Research
12
Peptide Therapeutics
Market
11-1-1 Rigorous researc! an" "e7elop*ent ;R=D< initiati7es
11-1-2 2n7esting in e*erging econo*ies
11-1-# 2n7esting in recent tec!nologies suc! as FPPS 1/c!nolog&
11-1-4 Mergers an" ac)uisitions
11-2 %arriers to e consi"ere"
11-2-1 1!e !ig! cost o+ pepti"e s&nt!esis
11-2-2 Gea. pipeline pepti"e "rug can"i"ates in p!ase 222
C!apter 12 Co*pan& ProBles
12-1 %ac!e* Fol"ing 58
12-1-1 Co*pan& o7er7ie(
12-1-2 3inancial o7er7ie(
12-1-# Strategic o7er7ie(
12-1-#-1 Collaorations
12-1-#-2 /6pansion
12-1-#-# Di7estiture
12-1-#-4 Recent "e7elop*ents
12-2 /li Lill& an" Co*pan&
12-2-1 Co*pan& o7er7ie(
12-2-2 3inancial o7er7ie(
Transparenc% Market Research
13
Peptide Therapeutics
Market
12-2-# Strategic o7er7ie(
12-2-#-1 5gree*ents
12-2-#-2 5ppro7als
12-2-4 Recent "e7elop*ents
12-# PBEer9 2nc-
12-#-1 Co*pan& o7er7ie(
12-#-2 3inancial o7er7ie(
12-#-# Strategic o7er7ie(
12-#-#-1 Mergers an" ac)uisitions
12-#-#-2 Di7estiture
12-#-#-# 5ppro7als
12-#-4 Recent "e7elop*ents
12-4 5*gen9 2nc-
12-4-1 Co*pan& o7er7ie(
12-4-2 3inancial o7er7ie(
12-4-# Strategic o7er7ie(
12-4-#-1 Mergers an" ac)uisitions
12-4-#-2 Licensing
12-4-4 Recent "e7elop*ents
12-5 1a.e"a P!ar*aceutical Co*pan& Li*ite"
Transparenc% Market Research
14
Peptide Therapeutics
Market
12-5-1 Co*pan& o7er7ie(
12-5-2 3inancial o7er7ie(
12-5-# Strategic o7er7ie(
12-5-#-1 Partners!ips an" collaorations
12-5-#-2 Mergers an" ac)uisitions
12-5-4 Recent "e7elop*ents
12-D 1e7a P!ar*aceuticals
12-D-1 Co*pan& o7er7ie(
12-D-2 3inancial o7er7ie(
12-D-# Strategic o7er7ie(
12-D-#-1 Mergers an" ac)uisitions
12-D-#-2 2n7esting in generic an" iosi*ilar seg*ents
12-D-4 Recent "e7elop*ents
12-7 LonEa 2nc-
12-7-1 Co*pan& o7er7ie(
12-7-2 3inancial o7er7ie(
12-7-# Strategic o7er7ie(
12-7-#-1 2n7esting in e*erging econo*ies
12-7-#-2 Mergers an" ac)uisitions
12-7-4 Recent "e7elop*ents
Transparenc% Market Research
1!
Peptide Therapeutics
Market
12-8 Peptis&nt!a
12-8-1 Co*pan& o7er7ie(
12-8-2 3inancial o7er7ie(
12-8-# Strategic o7er7ie(
12-8-#-1 5rranging an" participating in tra"e s!o(s
12-8-#-2 Continuous *anu+acturing e6pansion
12-9 SanoB
12-9-1 Co*pan& o7er7ie(
12-9-2 3inancial o7er7ie(
12-9-# Strategic o7er7ie(
12-9-#-1 5c)uisitions
12-9-#-2 Di7est*ents
12-9-4 Recent "e7elop*ents
12-10 2psen
12-10-1 Co*pan& o7er7ie(
12-10-2 3inancial o7er7ie(
12-10-# Strategic o7er7ie(
12-10-#-1 Large in7est*ent in researc! an" "e7elop*ent
12-10-#-2 8loal e6pansion t!roug! partners!ip
12-10-4 Recent "e7elop*ents
Transparenc% Market Research
12
Peptide Therapeutics
Market
12-11 Pol&Pepti"e 8roup-
12-11-1 Co*pan& o7er7ie(
12-11-2 Strategic o7er7ie(
12-11-2-1 3ocus on pro"uct port+olio e6tension an" )ualit& pro"uct "e7elop*ent
12-11-2-2 8loal e6pansion t!roug! *erger an" ac)uisition
12-12 5*&lin P!ar*aceuticals LLC $ %ristol$M&ers S)ui ;%MS<
12-12-1 Co*pan& o7er7ie(
12-12-2 5*&lin P!ar*aceuticals LLC
12-12-# 3inancial o7er7ie(
12-12-4 Strategic o7er7ie( ;5*&lin P!ar*aceuticals LLC<
12-12-4-1 /ntering into strategic collaorations
12-12-4-2 Corporate social responsiilit&
12-12-4-# Rigorous R=D initiati7es
12-12-5 Recent "e7elop*ents
12-1# 5straHeneca PLC
12-1#-1 Co*pan& o7er7ie(
12-1#-2 3inancial o7er7ie(
12-1#-# Strategic o7er7ie(
12-1#-#-1 Rigorous R=D initiati7es
12-1#-#-2 2n7esting in e*erging econo*ies
Transparenc% Market Research
1)
Peptide Therapeutics
Market
12-1#-4 Recent "e7elop*ents
12-14 Roc!e
12-14-1 Co*pan& o7er7ie(
12-14-2 3inancial o7er7ie(
12-14-# Strategic o7er7ie(
12-14-#-1 Researc! an" "e7elop*ent initiati7es
12-14-#-2 3ocus on personaliEe" !ealt!care
12-14-#-# 3ocus on ne( an" e*erging *ar.ets
12-14-#-4 3un"ing a(areness progra*s
12-14-4 Recent "e7elop*ents
12-15 8la6oS*it!Iline ;8SI<
12-15-1 Co*pan& o7er7ie(
12-15-2 3inancial o7er7ie(
12-15-# Strategic o7er7ie(
12-15-#-1 Researc! an" "e7elop*ent initiati7es
12-15-#-2 Direct to Consu*er 5"7ertising
12-15-#-# Mergers an" ac)uisitions
12-15-4 Recent "e7elop*ents
12-1D Merc. = Co-
12-1D-1 Co*pan& o7er7ie(
Transparenc% Market Research
1(
Peptide Therapeutics
Market
12-1D-2 3inancial o7er7ie(
12-1D-# Strategic o7er7ie(
12-1D-#-1 Corporate social responsiilit&
12-1D-#-2 R=D 2nitiati7es
12-1D-#-# Strategic alliances an" out$licensing
12-1D-4 Recent "e7elop*ents
12-17 'o7artis 58
12-17-1 Co*pan& o7er7ie(
12-17-2 3inancial o7er7ie(
12-17-# Strategic o7er7ie(
12-17-#-1 Mergers an" ac)uisitions
12-17-#-2 Me*oran"u* o+ un"erstan"ing
12-17-4 Recent "e7elop*ents
12-18 'o7o$'or"is. 5,S
12-18-1 Co*pan& o7er7ie(
12-18-2 3inancial o7er7ie(
12-18-# Strategic o7er7ie(
12-18-#-1 Partners!ips an" alliances
12-18-4 5gree*ents
12-18-5 Recent "e7elop*ents
Transparenc% Market Research
1"
Peptide Therapeutics
Market
Transparenc, Market &esearch is a arket intelli+ence copan, providin+ +lobal business in'oration
reports and services. >ur e/clusive blend o' 6uantitative 'orecastin+ and trends anal,sis provides 'orward=
lookin+ insi+ht 'or thousands o' decision akers.
@e are privile+ed with hi+hl, e/perienced tea o' $nal,sts- &esearchers and #onsultants- who use
proprietar, data sources and various tools and techni6ues to +ather- and anal,0e in'oration. >ur
business o.erin+s represent the latest and the ost reliable in'oration indispensable 'or businesses to
sustain a copetitive ed+e.
Contact:
Transparenc, Market &esearch
"0 State Street-
Suite )00-
$lban,
8A = 1220)
United States
TelB C1=!1(=21(=1030
US$ = #anada Toll Dree (22=!!2=34!3
<ailB salesEtransparenc,arketresearch.co
@ebsiteB httpBFFwww.transparenc,arketresearch.coF
Transparenc% Market Research
20
5out Us